Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Receptor tyrosine-protein kinase erbB-2 (HER2) is a member of the epidermal growth factor receptor (EGFR) family, playing a pivotal role in regulating cell growth, survival, and differentiation (UniProt P04626). Unlike other ErbB receptors, HER2 does not have a known high-affinity ligand and remains in an open, constitutively active conformation that facilitates dimerization with other ligand-bound ErbB members. The extracellular domain II (ECD II) is the specific region responsible for this dimerization, particularly the formation of the HER2-HER3 heterodimer, which is considered the most potent signaling pair in the family. In many cancers, HER2 is overexpressed or amplified, leading to uncontrolled signaling and tumor progression. Drugs like pertuzumab specifically target ECD II to sterically hinder dimerization, effectively shutting down oncogenic signaling pathways and providing a targeted therapeutic approach for HER2-positive malignancies (FDA Label: Perjeta).
Pertuzumab binds specifically to the extracellular dimerization domain (Domain II) of the HER2 protein, thereby blocking ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4 (FDA Label: Perjeta). This inhibition disrupts downstream signaling pathways such as the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways, leading to growth arrest and apoptosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Receptor tyrosine-protein kinase erbB-2 (HER2) extracellular domain II (HER2 ECD II).